Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary thromboendarterectomy

S W Jamieson

    Heart (British Cardiac Society)
    |April 16, 1998
    PubMed
    Summary
    This summary is machine-generated.

    Pulmonary thromboendarterectomy (PTE) offers a curative option for thromboembolic pulmonary hypertension, with a low mortality rate and improved survival. Physicians should identify patients for this potentially life-saving procedure.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Chronic thromboembolic pulmonary hypertension.

    Seminars in respiratory and critical care medicine·2005
    Same author

    Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension.

    The European respiratory journal·2004
    Same author

    Outpatient inhaled nitric oxide in a patient with idiopathic pulmonary fibrosis: a bridge to lung transplantation.

    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2001
    Same author

    Pulmonary thromboendarterectomy combined with other cardiac operations: indications, surgical approach, and outcome.

    The Annals of thoracic surgery·2001
    Same author

    Human angiopoietin gene expression is a marker for severity of pulmonary hypertension in patients undergoing pulmonary thromboendarterectomy.

    The Journal of thoracic and cardiovascular surgery·2001
    Same author

    Acquired aortopulmonary fistula in acute dissection.

    The Journal of thoracic and cardiovascular surgery·2001
    Same journal

    Refining evidence-based care for diverse bicuspid aortic valve phenotypes: addressing one piece of a larger puzzle.

    Heart (British Cardiac Society)·2026
    Same journal

    No pain, no gain? The complexity of ST-elevation myocardial infarction without chest pain.

    Heart (British Cardiac Society)·2026
    Same journal

    Is earlier better? Re-examining the timing of double sequential external defibrillation.

    Heart (British Cardiac Society)·2026
    Same journal

    Feasibility of early double sequential defibrillation in out-of-hospital cardiac arrest: the double-D randomised pilot trial.

    Heart (British Cardiac Society)·2026
    Same journal

    Correspondence on 'When a patent foramen ovale becomes pathological' by Saji and Ohara.

    Heart (British Cardiac Society)·2026
    Same journal

    Cost-effectiveness of N-terminal pro-B-type natriuretic peptide thresholds for echocardiography referral in primary care heart failure management.

    Heart (British Cardiac Society)·2026
    See all related articles

    Area of Science:

    • Cardiovascular Surgery
    • Pulmonary Hypertension Research
    • Thoracic Surgery

    Background:

    • Thromboembolic pulmonary hypertension (CTEPH) is a serious condition with limited treatment options.
    • Pulmonary thromboendarterectomy (PTE) is a potentially curative but underutilized surgical intervention.
    • Medical management for CTEPH yields unsatisfactory results, and lung transplantation has higher risks.

    Discussion:

    • PTE is considered hazardous by many, but our experience shows a low mortality rate (5-7%) and significant long-term benefits.
    • Compared to lung transplantation, PTE demonstrates superior long-term survival and fewer chronic complications.
    • The under-recognition of CTEPH contributes to the low number of PTE procedures performed globally.

    Key Insights:

    • PTE offers a favorable risk-benefit profile compared to lung transplantation for CTEPH.

    Related Experiment Videos

  • Sustained functional improvement is documented in PTE survivors.
  • The poor prognosis and limited efficacy of medical treatments underscore the need for alternative therapies.

    • Outlook:

    • Increased physician awareness and patient identification are crucial for wider adoption of PTE.
    • PTE should be considered the primary treatment for eligible patients with thromboembolic pulmonary hypertension.
    • Further research and training can enhance the accessibility and outcomes of PTE.